Fundraisings and IPOs

Date: 2017-03-22

Type of information: Fundraising

Company: Vect-Horus (France)

Investors: Provençale et Corse, BPMed (France)

Amount: € 2.5 million

Funding type: fundraising

Planned used: These funds will allow Vect-Horus to increase its technological lead in vectorisation and development of innovative therapeutic and imaging molecules for the treatment of indications with high unmet medical needs. Through its VECTrans® technology, the company provides ground-breaking solutions for innovation in high therapeutic needs indications such as central nervous system diseases and some cancers.

Others: * On March 22, 2017,  Vect-Horus, a French biotechnology leader in the design of vectors that facilitate the delivery of drugs into the brain and other organs, announced completion of a new fundraising round for 2.5 million euros, from private shareholders including Société de Capital Risque (SCR) Provençale et Corse, a wholly owned subsidiary of Banque Populaire Méditerranée (BPMed). Since its creation, the company has raised  over 17 M€, including 6 M€ in grants and research tax credit. Founded in 2005, the company is a spin-off from the CNRS-Aix Marseille University  NICN laboratory directed by Dr. Michel Khrestchatisky. Its founders are Alexandre Tokay, Chairman, and Michel  Khrestchatisky, Scientific Counsel.  Vect-Horus is dedicated to the design and the development of vectors to facilitate the delivery of drugs  or imaging agents into the brain and other organs. By combining pharmaceutical agents to its vectors, the company enables their transport across the blood brain barrier, which significantly impedes brain delivery of most drugs. The company has demonstrated proof of concept of the technology in animal models by developing different vectorized molecules, among them the endogenous neuropeptide neurotensin, which is in regulatory preclinical studies. The technology has also enabled the signing of a scientific collaboration agreement with Sanofi in the field of neurodegenerative diseases.  The company is also involved in the DHUNE program. This multidisciplinary university-hospital federation is accredited as a national and international excellence center for  neurodegenerative diseases with the aim of achieving significant progress on these diseases in the next 5 years.

Therapeutic area: CNS diseases - Neurological diseases - Neurodegenerative diseases - Cancer - Oncology

Is general: Yes